bristol branding inc

225 west 39th street, room 302
new york, new york 10018

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 21, 2014

NYS DOS ID#
4548780

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - BRISTOL BRANDING INC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Coach Inc. is changing its name, and shoppers are pissed
    By Reuters - Wednesday Oct 11, 2017

    Coach Inc will change its corporate name to Tapestry Inc, it said on Wednesday, as it creates a broader umbrella for its high-end brands without diluting the iconic name known mainly for selling luxury handbags. The company’s shares were down 2 percent in early trading following the announcement in which Tapestry will be the holding...

    Source: New York Post: Business
  • Man accused of burning girl with iron over wrinkled clothes
    By Associated Press - Friday Jul 28, 2017

    BRISTOL, Conn. — A Connecticut man has been arrested on charges that he intentionally burned his girlfriend’s 5-year-old daughter with an iron because she may have wrinkled his clothes. The Bristol Press reports that 33-year-old Victor Diaz, of Bristol, was arraigned Thursday on charges including assault and reckless endangerment. Investigators say he burned the girl...

    Source: New York Post: News
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
  • Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
    By Ben Fidler - Wednesday Aug 16, 2017

    The recent stumbles for cancer immunotherapy—specifically, combinations of treatments meant to help boost its effectiveness—continued late Tuesday with some disappointing news from one of the leaders in the field, Bristol-Myers Squibb. Bristol (NYSE: BMY) said that a Phase 3 trial testing two of its immunotherapies together in newly diagnosed kidney cancer patients, a study called […]

    Source: Xconomy New York
  • Food & Wine Magazine Will Leave New York for Alabama
    By STEPHANIE STROM - Friday Jun 23, 2017

    The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.

    Source: NYT > Home Page